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Abstract
Introduction: Juvenile idiopathic arthritis (JIA) often causes inflammation of the temporomandibular joint (TMJ)
and has been treated with both systemic and intra-articular steroids, with concerns about effects on growing
bones. In this study, we evaluated the impact of a macromolecular prodrug of dexamethasone (P-DEX) with
inflammation-targeting potential applied systemically or directly to the TMJ.
Methods: Joint inflammation was initiated by injecting two doses of complete Freund’s adjuvant (CFA) at 1-month
intervals into the right TMJs of 24 growing Sprague–Dawley male rats (controls on left side). Four additional rats
were not manipulated. With the second CFA injection, animals received (1) 5 mg of P-DEX intra-articularly (n = 9),
(2) 15 mg of P-DEX into the tail vein (n = 7), or (3) nothing in addition to CFA (n = 8). The rats were killed 28 days
later and measured by radiography for ramus height (condylar superior to gonion inferior [CsGoInf]), by micro-computed
tomography for condylar width (CW) and bone volume/standardized condylar volume (BV/CV), and by histology for
retrodiscal inflammatory cells. Inflammation targeting of systemic P-DEX was confirmed by IVIS infrared dye imaging.
Inflammation and bone growth were compared between groups using analysis of variance and Pearson’s correlations.
Results: CFA caused a significant reduction in CsGoInf (p < 0.05), but neither route of P-DEX administration had an effect
on CsGoInf or CW at CFA injection sites. BV/CV was significantly reduced in both inflamed and control condyles as a
result of either steroid application (p < 0.05). The inflammatory infiltrate was overwhelmingly lymphocytic, comprising
16.4 ± 1.3 % of the field in CFA alone vs. <0.01 % lymphocytes in contralateral controls (p < 0.0001). Both P-DEX TMJ
(10.1 ± 1.2 %) and systemic P-DEX (8.9 ± 1.7 %) reduced lymphocytes (p < 0.002). The total area of inflammatory infiltrate
was significantly less in the systemic injection group than in the group that received CFA injections alone (2.6 ± 1.5 mm2
vs. 8.0 ± 1.3 mm2; p = 0.009), but not in the group that received intra-articular P-DEX (8.8 ± 1.2 mm2).
Conclusions: High-dose systemic administration of inflammation-targeting P-DEX is more effective than an intra-articular
injection in reducing TMJ inflammation, but both routes may affect TMJ bone density.
Introduction
Juvenile idiopathic arthritis (JIA) is an inflammatory dis-
ease of the joints of unknown etiology. It begins before
the age of 16 years and lasts more than 6 weeks at a
time [1]. Magnetic resonance imaging showed that 87 %
of patients with newly diagnosed JIA had temporoman-
dibular joint (TMJ) inflammatory activity [2]. In a study
in which researchers evaluated the occurrence and
clinical signs and symptoms of TMJ involvement in pa-
tients diagnosed with JIA, 45 % of 97 children evaluated
had TMJ involvement [3]. More recently, 55 % of pa-
tients with JIA had at least one symptomatic TMJ and
78 % of radiographed individuals had condylar lesions
[4]. TMJ arthritis may cause limitations in sagittal and
vertical mandibular growth, which can result in micro-
gnathia and open bite. Many patients are required to
undergo orthodontic treatment or orthognathic surgery
to correct the deformities that result from the arthritic
destruction of the joint and associated growth distur-
bances [5]. Adult rheumatoid arthritis (RA) also has a
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high incidence of TMJ involvement. The authors of a re-
cent report of patients with RA showed that 57.9 % of
TMJs have spontaneous pain, 87.9 % have radiologic de-
struction, and 42.1 % have restricted mouth opening [6].
Inflammation and pain reduction are the primary goals
of pharmacologic therapy, including the use of steroids.
Intra-articular injections appear to be preferred over sys-
temic steroid applications for TMJ management in both
JIA and RA [7], presumably because of more localized
action and fewer systemic side effects and less impact on
other bones of the skeleton [8]. In a recent systematic
review, Stoustrup et al. [9] found that intra-articular
TMJ corticosteroid injections are successful in reducing
inflammation and orofacial symptoms in patients with
JIA, but evidence is lacking regarding whether the anti-
inflammatory behavior of the corticosteroids improves
maximal incisal opening or normalizes and/or improves
mandibular growth in these patients. In studies done in
rabbits, researchers have found that intra-articular
injections of corticosteroids caused a decrease in man-
dibular growth and that, on the basis of this evidence,
intra-articular corticosteroid injections would not be
appropriate in growing individuals [10]. Even in older
individuals with TMJ RA, steroid injections are not use-
ful for long-term or repeated treatment, as they lead to
collapse of the joint [11]. More conservative approaches
have been recommended.
Are there protocols that can concentrate steroids in
the TMJ without use of intra-articular injections? One
proposed option is dexamethasone iontophoresis, which
used low-grade electric currents for transdermal dexa-
methasone delivery into the TMJ [12]. An average of
eight sessions resulted in increased interincisor opening
in 68 % of patients with JIA and decreased TMJ pain in
73 %. Another possibility is a macromolecular prodrug
of dexamethasone (P-DEX) that can traverse highly per-
meable blood vessels, such as those found in inflamed
tissue associated with TMJ JIA or RA.
The present study was designed to evaluate inflam-
matory, growth, and morphologic changes associated
with P-DEX administration for juvenile rat TMJ inflam-
mation, delivered by either intra-articular (local) or tail
vein (systemic) injection. The hypothesis of this study
was that a single systemic high-dose P-DEX application
could reduce TMJ inflammation as effectively as local
P-DEX administration.
Methods
Complete Freund’s adjuvant–induced inflammation
All animals were treated and housed in the University of
Nebraska Medical Center (UNMC) College of Dentistry
Animal Facility, and ethical approval was obtained from
the UNMC Institutional Animal Care and Use Committee
(IACUC 10-70-FC). Juvenile rats were chosen because
they were experiencing rapid growth throughout our
study, so bone changes in the condyle during TMJ
inflammation and resulting from drug application could
be monitored.
Complete Freund’s adjuvant (CFA; 50 μg of heat-killed
Mycobacterium tuberculosis in paraffin oil) was injected
into the TMJ to induce inflammation according to the
protocol described by Harper et al. [13] and George et
al. [14]. The rats received two intra-articular injections
of 50 μl of CFA 4 weeks apart, at week 0 to initiate in-
flammation and at week 4 to boost inflammation in con-
junction with administration of experimental drugs.
Experimental groups
Group characteristics are summarized in Table 1. Group
1 (CFA) received 2 unilateral (right) TMJ intra-articular
injections of CFA alone at week 0 and week 4. Group 2
(CFA + P-DEX TMJ) received 2 unilateral TMJ intra-
articular injections of CFA (at week 0 and week 4). The
week 4 intra-articular injection was combined with 5 mg
of P-DEX. Group 3 (CFA + P-DEX Tail) received two
unilateral TMJ intra-articular injections of CFA (week 0
and week 4) and intravenous (tail vein) injection of
15 mg P-DEX at week 4. Before the core study, 4 rats re-
ceived 2 unilateral (right) TMJ intra-articular injections
of CFA (week 0 and week 4) and an intravenous (tail
vein) injection cocktail of a low dose of IRDye 800CW-
labeled P-DEX at week 4 to confirm that P-DEX could
concentrate in the inflamed TMJ (Fig. 1). Contralateral
joints (left side) of injected animals served as unmani-
pulated controls. Previous studies have shown some
inflammatory crossover effects [15]; therefore, Group 4
was included with no manipulation (both sides used).
All rats were euthanized at 8 weeks.
Drug preparation and application
Macromolecular P-DEX was synthesized by reversible
addition–fragmentation chain transfer (RAFT) copoly-
merization, as described previously [16]. Briefly, N-(2-
hydroxypropyl)methacrylamide (HPMA), N-methacry-
loylglycylglycylhydrazyl dexamethasone (MA-DEX), and
other comonomers (N-methacryloylaminopropyl fluo-
rescein thiourea and N-[3-aminopropyl]methacrylamide
hydrochloride[APMA]; Polysciences, Warrington, PA, USA)
were copolymerized at 40 °C under argon for 48 h with
2,2′-azobisisobutyronitrile as the initiator and S,S′-bis(α,α′-
dimethyl-α″-acetic acid)trithiocarbonate as the RAFT
agent [17]. The resulting polymers were purified by
Sephadex LH-20 column chromatography (GE Healthcare
Bio-Sciences, Pittsburgh, PA, USA) and lyophilized. IRDye
800CW-labeled P-DEX (P-DEX-IRDye) was obtained via
polymer-analogous reactions between poly(HPMA-co-
MA-DEX-co-APMA) and N-hydroxysuccinimide esters of
the dye [18].
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Anesthesia and killing of the rats
Anesthesia was induced by placing the rats into an incuba-
tion chamber with 1–4 % isoflurane/100 % O2 (1–3 L/min)
and maintained with a nose cone and 0.5–2 % isoflurane/
100 % O2 (0.5–1 L/min) during the injections. The rats
were killed by CO2 asphyxiation. Their skulls were placed
in 10 % formalin for storage before radiographic analysis,
then dissected to retain the head of the condyle, fossa, and
retrodiscal area for micro-computed tomography (μCT)
and histologic analysis.
IVIS IRDye measurements
P-DEX-IRDye (1 mg/rat; n = 4 rats) was injected into the
tail vein and imaging in the XENOGEN IVIS-200 in vivo
imaging system (PerkinElmer, Waltham, MA, USA) was
performed at 1, 2, 4, 8, and 12 h after tail vein injections,
then daily for 1 week. The signal intensity was quantita-
tively analyzed using the resident software (Living Image;
PerkinElmer). This method is similar to the method used
by Ren et al. [18] with a mouse model.
Radiographic measurements
Radiographic measurements of the right and left sides of
all of the rat heads were taken before μCT evaluation.
The specimens were all split along the midsagittal plane.
The measurements were obtained by using a digital
Kodak sensor (Kodak RVG 6100; Carestream Health,
Rochester, NY, USA). The sensor was fixed to a table for
stability, and the cone was positioned on the mounting
table so that the x-ray source, specimen, and sensor
dimensions were standardized. Digital radiographs were
taken of the right and left sides, with the exposure set at
0.125 seconds. Orthodontic wire 5 mm in length was
used as a calibration tool in each radiograph. Radio-
graphs were stored and measurements were obtained
using MiPACS Dental Enterprise Viewer 3.1.1326 software
(Medicor Imaging, Charlotte, NC, USA). The images were
properly oriented by using the “protractor tool” to meas-
ure an angle of 92 degrees from the condyle to the inferior
border of the ramus. From this reference angle, two points
were identified: (1) condylar superior (Cs), the most super-
ior point on the mandibular condyle; and (2) gonion infer-
ior (GoInf), the most inferior point on the mandibular
ramus. Next, CsGoInf (ramus height) was measured as
the distance between the condylar superior and gonion
inferior.
Micro-computed tomography measurements
The units were scanned with a high-resolution system
(SkyScan1172; Bruker microCT, Madison, WI, USA)
using a method described previously [19]. All specimens
were aligned on three axes (sagittal, coronal, and trans-
axial) until the head of the condyle from each view was
centered in each frame. The coronal views designated by
the SkyScan1172 software were used to obtain the mea-
surements. Bone volume (BV) measurements were taken
in the condyle in the total volume of interest, which was a
0.784 × 0.784 × 0.784-mm cube, representing the largest
cube that could fit within all condyles while touching the
superior border of the condyle. The cube occupied more
than 50 % of the total condylar volume. The largest
Table 1 Experimental groups
Group Animals, n Week 0 Week 4 Week 8
1 (CFA) 8 TMJ CFA TMJ CFA Killed
2 (CFA + P-DEX TMJ) 9 TMJ CFA TMJ CFA + P-DEX TMJ Killed
3 (CFA + P-DEX tail) 7 TMJ CFA TMJ CFA + P-DEX tail Killed
4 (no manipulation) 4a – – Killed
CFA complete Freund’s adjuvant, P-DEX prodrug of dexamethasone, TMJ temporomandibular joint
aBoth TMJs evaluated in each animal
Fig. 1 IVIS image obtained 3 days after 1 mg of prodrug of
dexamethasone infrared dye was injected into the tail vein. Note
intensity of color concentrated in the temporomandibular joint area
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condylar width (CW) measurement for each condyle was
also taken from the coronal views.
Histologic measurements
Following μCT analysis, specimens were decalcified in
5 % formic acid at 4 °C for 2 weeks, blocked in a sagittal
plane through the TMJ, and embedded in paraffin, and
5-μm sections were cut through the TMJ and stained
with hematoxylin and eosin to reveal the head of the
condyle, disc, and retrodiscal soft tissue. Using a digital
microscope charge-coupled device camera and software
(ProgRes; JENOPTIK, Jena, Germany), the area of in-
flammatory infiltrate (×100 magnification) was assessed
in the entire area of the retrodiscal tissue as determined
by two independent evaluators without knowledge of ex-
perimental group, cell counts were conducted in two
100-point grids (×400) in the center of the retrodiscal
tissue, and all data were averaged. Also, the proper loca-
tion of TMJ injections was confirmed by the appearance
of CFA oil droplets in the retrodiscal soft tissue.
Statistical analysis
Eight rats per group were assigned based on histological
detection of a significant decrease in inflammation with
administration of anti-inflammatory drugs in intra-
articular injections [14]. Also, analysis of previous data
[19] indicated that seven or eight rats would be neces-
sary to show a statistically significant ≥10 % difference in
ramus height growth among various anti-inflammatory
agents, a change likely to show signs of open bite or
other growth disturbances in humans requiring orthodon-
tic therapy. Specimens were coded by animal and side
(right or left) and measured by two examiners without
knowledge of group designation. Each examiner repeated
these measurements 2 weeks later by remeasuring 10 % of
the original specimens. Analysis of variance was used for
intergroup comparisons, and Pearson’s correlation co-
efficients were calculated to compare measurements.
Repeated measures of 10 % of the specimens with a
mixed-effects model repeated-measures analysis showed
that the estimated variance among animals was much
greater than the residual estimate (p < 0.0001), indi-
cating high reproducibility [19]. Results were reported
as mean ± standard deviation or change between ex-
perimental and control sides and were considered sig-
nificant when p values were ≤0.05.
Results
One animal died prematurely of unknown cause after
administration of CFA at week 4. All other animals tol-
erated the procedures well. Rats in all groups ingested
similar amounts of food and water, and none showed ab-
normal signs of pain or stress (piloerection, scratching at
the jaw) beyond porphyrin staining during the first 2–3
days following TMJ injections in all groups. Uneven
numbers in groups were due to inability to complete the
tail vein injection in one rat (CFA + P-DEX Tail), which
was switched to CFA + P-DEX TMJ.
Radiographic measurements
The radiographic data for change in ramus height from
contralateral controls (CsGoInf ) are shown in Fig. 2.
The group with no manipulation had statistically more
ramus height than all other groups, including CFA alone.
Although tail or TMJ steroid injection did not cause fur-
ther reduction in growth with CFA-induced inflammation,
steroid application did not normalize growth. When the
contralateral control mandibles were compared, those
contralateral to CFA + P-DEX TMJ and CFA + P-DEX tail
vein injections were statistically smaller than the ones
Fig. 2 Change in ramus height for each manipulation minus its contralateral control (Cs-GoInf) 8 weeks after baseline. Brackets define statistical
differences between experimental groups (sides). *p < 0.05, **p < 0.01. CFA complete Freund’s adjuvant, P-DEX prodrug of dexamethasone,
TMJ temporomandibular joint
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contralateral to the no-manipulation group. However,
both rami contralateral to P-DEX sides had significantly
greater ramus height than the experimental sides.
Micro-computed tomography measurements
No statistically significant differences between groups or
between manipulated vs. unmanipulated sides were seen
for greatest CW. Differences in the bone volumetric
measurement within a standardized condylar volume
(BV/CV) between groups showed that the CFA + P-DEX
TMJ and CFA + P-DEX tail groups had statistically less
BV than the CFA alone or no-manipulation groups. Fur-
thermore, CFA + P-DEX tail BV/CV was less than that
in the CFA + P-DEX TMJ group. The contralateral con-
trols for the CFA + P-DEX TMJ injection group and the
CFA + P-DEX tail injection group had statistically less
BV than the CFA contralateral control group and the
no-manipulation control group. Also, the contralateral
control site had statistically more BV than its CFA-alone
side. However, the decrease in contralateral BV/CV re-
sulted in little or no decrease in P-DEX BV/CV when
subtracted from the experimental side (Fig. 3).
Histologic measurements
Histologic measures of inflammation are summarized in
Table 2. All experimental TMJs with CFA injections had
highly significant (p < 0.0001) larger inflammatory infiltrates
than contralateral controls (negligible infiltrate), except for
the CFA + P-DEX tail group, which was not statistically
different from contralateral controls. The inflammatory
infiltrates were overwhelmingly lymphocytic. The percent-
age of lymphocytes was statistically higher in the CFA
alone group vs. P-DEX TMJ or P-DEX tail group, and the
P-DEX tail group had fewer lymphocytes than the P-DEX
TMJ group. Plasma cells and macrophages were not
present at more than 0.5 % in any tissues except CFA
alone (0.7 ± 0.1 % and 0.6 ± 0.1 %, respectively). Con-
nective tissue without infiltrate comprised the majority of
retrodiscal tissue, inversely proportional to the lymphocyte
infiltrate (Table 2). Whereas the CFA + P-DEX TMJ,
CFA + P-DEX tail, and no-manipulation groups had more
connective tissue than CFA alone, none of the three were
significantly different from each other.
Significant correlations between ramus height and histo-
logic levels of inflammation were found. The area of in-
flammatory infiltrate and percentage of lymphocytes were
negatively correlated with CsGoInf (r = −0.31 and −0.40,
respectively; p < 0.01), whereas the percentage of non-
inflamed retrodiscal connective tissue was positively cor-
related with CsGoInf (r = 0.36, p = 0.004).
Discussion
The experimental TMJ inflammation model using two
CFA TMJ injections in this study was successful in sustain-
ing inflammation for 4 weeks following the second injec-
tion (Table 2). In addition, ramus height in the CFA group
was significantly smaller than in the no-manipulation
group (Fig. 2) and was correlated with the markers of in-
flammation, as likely occurs with unpaired micrognathia
and resulting deformities seen in JIA [20].
A single dose of dexamethasone, a representative
steroid, was applied either locally or systemically in a
P-DEX preparation with the primary goal of reducing
TMJ inflammation. The systemic delivery was accom-
plished with the P-DEX tail group, in which the area of in-
flammatory infiltrate and percentage of lymphocytes were
significantly reduced compared with CFA alone (Table 2).
Local delivery of P-DEX TMJ also reduced the percentage
of lymphocytes compared with CFA alone, but the area of
infiltrate and percentage of lymphocytes were lower in the
Fig. 3 Change in condylar bone volume within standardized condylar volume of interest for each manipulation minus its contralateral control
(BONEVC) 8 weeks after baseline. Brackets define statistical differences between experimental groups (sides). *p < 0.05, **p < 0.01, ***p < 0.0001.
CFA complete Freund’s adjuvant, P-DEX prodrug of dexamethasone, TMJ temporomandibular joint
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P-DEX tail group than in the P-DEX TMJ group. Al-
though systemic steroids can be effective in reducing TMJ
inflammation [21, 22], these findings suggest that systemic
P-DEX was superior in reducing inflammation, probably
owing to using a passive targeting mechanism termed
“extravasation through leaky vasculature and the subse-
quent inflammatory cell-mediated sequestration (ELVIS)”
[23]. Because JIA usually involves other joints in addition
to TMJs, P-DEX has the advantage of selectively targeting
any inflamed joint [24, 25]. The distribution of a con-
ventional systemic steroid to the TMJ may be 1–2 % of
the initial dose, far less than the 33 % differential between
P-DEX TMJ and systemic P-DEX according to our expe-
rience with the adjuvant-induced arthritis (AA) rat model.
The concentration of drug at the site of inflammation may
help explain why patients with JIA taking conventional
systemic steroids continue to have TMJ symptoms but are
helped (increased maximal incisal opening and reduced
arthritic changes observed by magnetic resonance imaging)
by a targeted approach of steroid delivery such as intra-
articular corticosteroid injections [8]. Systemic P-DEX
represents another targeted approach with potentially re-
duced morbidity relative to intra-articular corticosteroid in-
jections. The accumulation of P-DEX in the TMJ, using
IRDye P-DEX at a lower dose (1 mg = 3 mg/kg) sup-
ports the premise that the P-DEX can leak from
inflamed vessels in TMJ inflammatory arthritis through
the ELVIS mechanism.
Bone quality in the condyle was affected by P-DEX via
both administration routes. BV was significantly reduced by
P-DEX on the CFA-inflamed side compared with no ma-
nipulation or CFA alone. Systemic steroids have tradition-
ally been associated with reduction in BV and bone density
in patients with rheumatologic diseases [26, 27], including
children with JIA [28]. Local steroids also have shown dis-
ruption of TMJ bone quality in animal models. Stoustrup et
al. [10], using 10-week-old female New Zealand white rab-
bits that had Freund’s incomplete adjuvant– or CFA-
induced TMJ arthritis and that were treated with triam-
cinolone hexacetonide in each TMJ at four different time
points or were left untreated, found that the rabbits that
were treated with the corticosteroid had unfavorable man-
dibular growth alterations compared with the untreated
arthritis and control groups. El-Hakim et al. [29] evaluated
the response to intra-articular TMJ injections of dexa-
methasone following mechanical induction of synovitis.
Histologically, they found that the condylar heads injected
with dexamethasone showed resorption with active osteo-
clastic activity after only one injection.
Condyles contralateral to both P-DEX applications
generally showed reduced BV and bone density com-
pared with no manipulation or CFA alone. This finding
Table 2 Histologic inflammation measurements in TMJ retrodiscal tissue
CFA complete Freund’s adjuvant, P-DEX prodrug of dexamethasone, TMJ temporomandibular joint
*p < 0.05, **p < 0.01, ***p < 0.0001
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confirms that systemic P-DEX was affecting bone quality
in other joints, but it also indicates that P-DEX TMJ had
some carryover effect on bone quality in the unmanipu-
lated TMJ. Therefore, the present study and past results
indicate that problems with bone quality associated with
high-dose TMJ-targeting steroid strategies still need to
be resolved. However, following JIA remission and/or
discontinuation of steroids, there is clinical evidence that
partial catch-up usually occurs in linear bone growth
[30] and bone mineral density may return to normal in
adulthood [31]. Long-term evidence in human craniofa-
cial growth is lacking [9], but rapid remission of arthritis
within the TMJ may act to eventually minimize the im-
pact on BV and bone density loss seen in the present
animal study.
P-DEX was given at high doses in the TMJ (5 mg =
15 mg/kg) and tail vein (15 mg = 45 mg/kg) based on
our experience in treating AA and in the lupus nephritis
mouse model (10 mg/kg and 30 mg/kg, respectively).
Typical anti-inflammatory doses of human intravenous
pulses of dexamethasone are 15–30 mg/kg given for 1–3
consecutive days and then continued every 2–4 weeks
until response or as needed [32]. A primary benefit of
intermittent pulse intravenous steroid therapy and local
therapy through joint injections is the desired reduction
in inflammation, but with the potential of limiting the
daily exposure of steroids seen with oral systemic dosing.
Daily oral steroids, when used over periods of months to
years, typically result in overall doses exceeding the
amount given by intermittent local or pulse intravenous
doses. This daily steroid exposure is what contributes
most to the increased side effects of steroids, including
systemic adrenal suppression, generalized growth suppres-
sion, osteoporosis, obesity, chronic hypertension, im-
munosuppression, mood swings, poor sleep, cushingoid
features, and avascular necrosis, further limiting their ap-
peal for chronic use in children [32]. As a result, the
chronic side effects of daily oral steroid exposure are often
felt to be more harmful in the long term than the rela-
tively rare side effects of local joint injections, such as sub-
cutaneous soft tissue atrophy caused by steroid leakage
out of the joint; localized intra-articular calcification,
which rarely is clinically symptomatic; and the very rare
joint infection. Similarly, the transient side effects of inter-
mittent pulse intravenous steroid administration, such as
acute hypertension, hyperglycemia, tachycardia, and acute
mood swings, are usually preferable to the chronic chan-
ges seen with daily dosing. Therefore, the use of local joint
injections or intermittent high-dose pulse intravenous
therapy, particularly with inflammation-targeting capabil-
ities, may be more ideal options for local TMJ arthritis,
given their avoidance of daily exposure to and thereby re-
duction of the chronic side effects seen with daily cortico-
steroid exposure.
Conclusions
Taken together, these data suggest the following. (1) Sys-
temic application of P-DEX has the potential to concentrate
in inflamed TMJs and reduce inflammation. (2) Systemic
and intra-articular applications of P-DEX have no effect
on ramus height or CW in growing rats with CFA-
induced inflammation, but bone quality is affected. (3)
TMJ inflammation appears to be associated with reduced
ramus and condylar growth. (4) Further studies of sys-
temic applications of P-DEX for treatment of TMJ inflam-
mation, especially dosing optimizations, are warranted in
both children and adults.
Abbreviations
AA: adjuvant-induced arthritis; APMA: N-(3-aminopropyl)methacrylamide
hydrochloride; BV: bone volume; CFA: complete Freund’s adjuvant;
CsGoInf: condylar superior to gonion inferior (ramus height); CV: standardized
condylar volume; CW: condylar width; ELVIS: extravasation through leaky
vasculature and the subsequent inflammatory cell-mediated sequestration;
HPMA: N-(2-hydroxypropyl)methacrylamide; IRDye: infrared dye; JIA: juvenile
idiopathic arthritis; MA-DEX: N-methacryloylglyclyglycylhydrazyl
dexamethasone; μCT: micro-computed tomography; P-DEX: prodrug of
dexamethasone; P-DEX-IRDye: prodrug of dexamethasone labeled with
IRDye 800CW infrared dye; RA: rheumatoid arthritis; RAFT: reversible
addition–fragmentation chain transfer; TMJ: temporomandibular joint;
UNMC: University of Nebraska Medical Center.
Competing interests
DW was the lead inventor of the P-DEX technology, and a Patent Cooperation
Treaty patent application has been filed for P-DEX. The other authors declare
that they have no competing interests.
Authors’ contributions
MK and MB performed histologic preparations and analyses. CH performed
CFA and drug delivery to the TMJs and radiographic and μCT measurements.
ALR developed the research design and clinical relevance. FY prepared all
P-DEX materials. YZ did the μCT scanning and optical imaging. PG confirmed
histological measurements and interpretation. DBM performed statistical
analyses. DW and RAR conceived of the study and participated in its design.
RAR coordinated the study and drafted the manuscript. All authors were
involved with revising the manuscript, approved the final version, and agree to
be accountable for all aspects of the work.
Acknowledgments
The authors thank Marian Schmid for her excellent technical assistance and
Susan McCoy for manuscript preparation. This work was supported by grants
from the University of Nebraska Foundation, Department of Growth and
Development and Student Research Program, and the Regenerative Medicine
Program University of Nebraska Medical Center. This work also was supported
in part by the National Institute of Arthritis and Musculoskeletal and Skin
Diseases of the National Institutes of Health under award number R01 AR62680.
FY and YZ acknowledge graduate fellowship support from the University of
Nebraska Medical Center.
Author details
1University of Nebraska Medical Center College of Dentistry, 4000 East
Campus Loop South, Lincoln, NE 68583-0740, USA. 2Private Practice of
Orthodontics, Cheyenne, WY, USA. 3Pediatric Rheumatology, Children’s
Hospital, Omaha, NE, USA. 4University of Nebraska Medical Center College of
Pharmacy, Omaha, NE, USA. 5Department of Statistics, University of Nebraska,
Lincoln, NE, USA.
Received: 7 January 2015 Accepted: 3 September 2015
References
1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369:767–78.
Knudsen et al. Arthritis Research & Therapy  (2015) 17:267 Page 7 of 8
2. Küseler A, Pedersen TK, Herlin T, Gelineck J. Contrast enhanced magnetic
resonance imaging as a method to diagnose early inflammatory changes in
the temporomandibular joint in children with juvenile chronic arthritis.
J Rheumatol. 1998;25:1406–12.
3. Twilt M, Mobers SM, Arends LR, ten Cate R, van Suijekom-Smit L.
Temporomandibular involvement in juvenile idiopathic arthritis.
J Rheumatol. 2004;31:1418–22.
4. Billiau AD, Hu Y, Verdonck A, Carels C, Wouters C. Temporomandibular joint
arthritis in juvenile idiopathic arthritis: prevalence, clinical and radiologic signs,
and relation to dentofacial morphology. J Rheumatol. 2007;34:1925–33.
5. von Bremen J, Ruf S. Orthodontic and dentofacial orthopedic management
of juvenile idiopathic arthritis: a systematic review of the literature. Orthod
Craniofac Res. 2011;14:107–15.
6. Bono AE, Learreta JA, Rodriguez G, Marcos JC. Stomatognathic system
involvement in rheumatoid arthritis patients. Cranio. 2014;32:31–7.
7. Ringold S, Tzaribachev N, Cron RQ. Management of temporomandibular
joint arthritis in adult rheumatology practices: a survey of adult
rheumatologists. Pediatr Rheumatol Online J. 2012;10:26.
8. Stoll ML, Good J, Sharpe T, Beukelman T, Young D, Waite PD, et al. Intra-articular
corticosteroid injections to the temporomandibular joints are safe and appear to
be effective therapy in children with juvenile idiopathic arthritis. J Oral Maxillofac
Surg. 2012;70:1802–7.
9. Stoustrup P, Kristensen KD, Verna C, Küseler A, Pedersen TK, Herlin T.
Intra-articular steroid injection for temporomandibular joint arthritis in
juvenile idiopathic arthritis: a systematic review on efficacy and safety.
Semin Arthritis Rheum. 2013;43:63–70.
10. Stoustrup P, Kristensen KD, Küseler A, Gelineck J, Cattaneo PM, Pedersen TK,
et al. Reduced mandibular growth in experimental arthritis in the
temporomandibular joint treated with intra-articular corticosteroid. Eur J
Orthod. 2008;30:111–9.
11. Sidebottom AJ, Salha R. Management of the temporomandibular joint in
rheumatoid disorders. Br J Oral Maxillofac Surg. 2013;51:191–8.
12. Mina R, Melson P, Powell S, Rao M, Hinze C, Passo M, et al. Effectiveness of
dexamethasone iontophoresis for temporomandibular joint involvement in
juvenile idiopathic arthritis. Arthritis Care Res. 2011;63:1511–6.
13. Harper RP, Kerins CA, McIntosh JE, Spears R, Bellinger LL. Modulation of the
inflammatory response in the rat TMJ with increasing doses of complete
Freund’s adjuvant. Osteoarthritis Cartilage. 2001;9:619–24.
14. George MD, Owen CM, Reinhardt AL, Giannini PJ, Marx DB, Reinhardt RA.
Effect of simvastatin injections on temporomandibular joint inflammation in
growing rats. J Oral Maxillofac Surg. 2013;71:846–53.
15. Hutchins B, Spears R, Hinton RJ, Harper RP. Calcitonin gene-related peptide
and substance P immunoreactivity in rat trigeminal ganglia and brainstem
following adjuvant-induced inflammation of the temporomandibular joint.
Arch Oral Biol. 2000;45:335–45.
16. Liu XM, Quan LD, Tian J, Alnouti Y, Fu K, Thiele GM, et al. Synthesis and
evaluation of a well-defined HPMA copolymer–dexamethasone conjugate
for effective treatment of rheumatoid arthritis. Pharm Res. 2008;25:2910–9.
17. Lai JT, Filla D, Shea R. Functional polymers from novel carboxyl-terminated
trithiocarbonates as highly efficient RAFT agents. Macromolecules.
2002;35:6754–6.
18. Ren K, Purdue PE, Burton L, Quan LD, Fehringer EV, Thiele GM, et al. Early
detection and treatment of wear particle-induced inflammation and bone
loss in a mouse calvarial osteolysis model using HPMA copolymer
conjugates. Mol Pharm. 2011;8:1043–51.
19. Holwegner C, Reinhardt AL, Schmid MJ, Marx DB, Reinhardt RA. Impact of
local steroid or statin treatment of experimental temporomandibular joint
arthritis on bone growth in young rats. Am J Orthod Dentofacial Orthop.
2015;147:80–8.
20. Kjellberg H, Fasth A, Kiliaridis S, Wenneberg B, Thilander B. Craniofacial
structure in children with juvenile chronic arthritis (JCA) compared with
healthy children with ideal or postnormal occlusion. Am J Orthod
Dentofacial Orthop. 1995;107:67–78.
21. Pedersen A, Klausen B. Glucocorticosteroids and oral medicine. J Oral
Pathol. 1984;13:1–15.
22. Swift JQ, Roszkowski MT, Alton T, Hargreaves KM. Effect of intra-articular versus
systemic anti-inflammatory drugs in a rabbit model of temporomandibular
joint inflammation. J Oral Maxillofac Surg. 1998;56:1288–96.
23. Wang D, Goldring SR. The bone, the joints and the Balm of Gilead. Mol
Pharm. 2011;8:991–93.
24. Quan LD, Yuan F, Liu XM, Huang JG, Alnouti Y, Wang D. Pharmacokinetic
and biodistribution studies of N-(2-hydroxypropyl)methacrylamide (HPMA)
copolymer–dexamethasone conjugates in adjuvant-induced arthritis rat
model. Mol Pharm. 2010;7:1041–9.
25. Yuan F, Quan LD, Cui L, Goldring SR, Wang D. Development of
macromolecular prodrug for rheumatoid arthritis. Adv Drug Deliv Rev.
2012;64:1205–19.
26. Tang XL, Qin L, Kwok AW, Zhu TY, Kun EW, Hung VW, et al. Alterations in
bone geometry, density, microarchitecture, and biomechanical properties in
systemic lupus erythematosus on long-term glucocorticoid: a case–control
study using HR-pQCT. Osteoporos Int. 2013;24:1817–26.
27. Lems WF. Are glucocorticoids harmful to bone in early rheumatoid arthritis?
Ann NY Acad Sci. 2014;1318:50–4.
28. Falcini F, Bindi G, Simonini G, Stagi S, Galluzzi F, Masi L, et al. Bone status
evaluation with calcaneal ultrasound in children with chronic rheumatic
diseases. A one year followup study. J Rheumatol. 2003;30:179–84.
29. El-Hakim IE, Abdel-Hamid IS, Bader A. Temporomandibular joint (TMJ)
response to intra-articular dexamethasone injection following mechanical
arthropathy: a histological study in rats. Int J Oral Maxillofac Surg.
2005;34:305–10.
30. Simon D, Fernando C, Czernichow P, Prieur AM. Linear growth and final
height in patients with systemic juvenile idiopathic arthritis treated with
longterm glucocorticoids. J Rheumatol. 2002;29:1296–300.
31. Thornton J, Ashcroft D, O’Neill T, Elliott R, Adams J, Roberts C, et al. A
systematic review of the effectiveness of strategies for reducing fracture
risk in children with juvenile idiopathic arthritis with additional data on
long-term risk of fracture and cost of disease management. Health Technol
Assess. 2008;12(3).
32. Murray KJ, Lovell DJ. Advanced therapy for juvenile arthritis. Best Pract Res
Clin Rheumatol. 2002;16:361–78.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Knudsen et al. Arthritis Research & Therapy  (2015) 17:267 Page 8 of 8
